HOME >> BIOLOGY >> NEWS
Active psoriatic arthritis patients on REMICADE achieve major clinical response in arthritis

SAN DIEGO, CALIF., NOVEMBER 13, 2005 New data, including two-year treatment duration, show a significantly higher proportion of patients with active psoriatic arthritis receiving REMICADE (infliximab) achieved and sustained a high degree of clinical improvement in arthritis, as assessed using the rheumatoid arthritis (RA) definition for "major clinical response," compared with patients receiving placebo. "Major clinical response" is defined as maintenance of a 70 percent improvement in the American College of Rheumatology score (ACR 70) for six continuous months. REMICADE maintenance therapy also resulted in the inhibition of structural damage and significant improvements in functional status and quality of life as maintained over the course of one year. Investigators will present these long-term Phase 2 and 3 study findings this week at the American College of Rheumatology 2005 Annual Scientific Meeting. REMICADE is currently indicated for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis.

"Previous study findings have shown the rapidity and therapeutic intensity of infliximab in treating the joint and skin manifestations associated with active psoriatic arthritis," said Arthur Kavanaugh, MD, Director, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, and lead study investigator. "These data demonstrate the rapid efficacy of infliximab can be sustained over time, especially as it relates to the arthritic component of this complex disease."

An analysis of two double-blind, placebo-controlled trials, Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) and Induction and Maintenance Psoriatic Arthritis Clinical Trial 2 (IMPACT 2), followed patients for two years (98 weeks) and one year (54 weeks), respectively, and confirmed a significant, high degree of clinical responses in the arthritic component of the disease. Placebo p
'"/>

Contact: Michael Parks
215-325-4010
Centocor, Inc.
16-Nov-2005


Page: 1 2 3 4

Related biology news :

1. Active lifestyle reduces risk of invasive breast cancer
2. Active ingredient in common Chinese herb shown to reduce hypertension
3. Active inbreeding avoidance in wild capuchin monkeys
4. UD awarded $11M for osteoarthritis research and unique mentoring program for women scientists
5. Breakthrough developments in rheumatoid arthritis reported
6. University of Manchester researchers reveal clues to new genes behind rheumatoid arthritis
7. Cartilage discovery offers arthritis hope
8. Rock climbing does not increase risk of osteoarthritis
9. U-M study offers new perspective on nitric oxide signaling in rheumatoid arthritis
10. Turmeric prevents experimental rheumatoid arthritis, bone loss, University of Arizona study shows
11. Can Gleevec help patients with rheumatoid arthritis?

Post Your Comments:
(Date:10/29/2014)... bodies decompose, their types and numbers of bugs ... could mean the difference between a closed case ... is using a more than $866,000 U.S. Department ... examine these changing populations. The microbial communities may ... death, gender, race, socioeconomic relations and more, said ...
(Date:10/29/2014)... new research potential of the Barcode of Life ... the Biodiversity Data Journal (BDJ) ... and imported these into a human-readable text developed in ... Data were used to study the species distributions of ... subfamily. , BOLD is originally designed to support the ...
(Date:10/29/2014)... is a hormone released by the stomach and it ... as a psychoactive substance that primarily affects brain function, ... , This knowledge, combined with findings from animal studies, ... potential to stimulate alcohol craving. , Dr. Lorenzo Leggio ... that, as they had anticipated, alcohol craving was increased ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
(Date:10/30/2014)... 2014 A new report, commissioned by BioCrossroads ... an in-depth look at Indiana,s ... over two different time frames: 1993 to 2002 and ... future opportunities for investment growth.  The Life Science ... report shows gains in innovation dollars as well as an ...
(Date:10/30/2014)... 29, 2014) – The severe flooding that devastated a ... less destructive if the bridges, roads and other infrastructure ... study from the University of Colorado Denver. , "People ... said Jimmy Kim, PhD, associate professor of structural engineering ... Science and lead author the study. "There is an ...
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
(Date:10/27/2014)... October 27, 2014 The “Molecular ... Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End ... Service, Software) - Global Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5CU Denver study says upgrading infrastructure could reduce flood damage 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5
Cached News: